Volatile anesthetics selectively alter [3H]ryanodine binding to skeletal and cardiac ryanodine receptors

Volatile anesthetics selectively alter [3H]ryanodine binding to skeletal and cardiac ryanodine receptors

Vol. 186, No. 1, 1992 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS July 15, 1992 Pages 595-500 VOLATILE ANESTHETICS SELECTIVELY ALTER ['H]R...

421KB Sizes 0 Downloads 80 Views

Vol. 186, No. 1, 1992

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

July 15, 1992

Pages 595-500

VOLATILE ANESTHETICS SELECTIVELY ALTER ['H]RYANODINE BINDING TO SKELETAL AND CARDIAC RYANODINE RECEPTORS*

Timothy J. Connelly a, Roque-El H a y e k a'b, B e n F. Rusy a a n d Roberto Coronado b D e p a r t m e n t s of aAnesthesiology and bphysiology, University of Wisconsin-Madison, Madison, Wisconsin 5 3 7 9 2

Received

June

i, 1992

SUMMARY. The effect of clinical concentrations of volatile a n e s t h e t i c s on r y a n o d i n e receptors of cardiac a n d skeletal m u s c l e sarcoplasmic reticulum w a s evaluated u s i n g [3H]ryanodine binding. At 2 volume percent, halothane a n d enflurane stimulated binding to cardiac SR b y 238% a n d 204%, respectively, while isoflurane h a d no effect. In contrast, h a l o t h a n e a n d enflurane h a d no effect on [3H]ryanodine binding to skeletal ryanodine receptors, while isoflurane p r o d u c e d a significant stimulation. These results s u g g e s t t h a t volatile a n e s t h e t i c s interact in a site-specific m a n n e r with r y a n o d i n e receptors of cardiac or skeletal m u s c l e to effect Ca 2÷ releasec h a n n e l gating. ®1992AcademicP.........

Halothane, anesthetics

that

evidence s u g g e s t s

isoflurane

and

enflurane

are

halogenated

inhallational

d e p r e s s myocardial contractility (1). A p r e p o n d e r a n c e that

excitation-contraction

these

coupling

agents

restrict the

(2). This

alteration

of

availability of Ca 2÷ for may

result

from

an

i m p a i r m e n t of the Ca 2. u p t a k e a n d release b y the SIR, although a specific target h a s n o t b e e n identified. Ca 2÷ release from the SR of cardiac and skeletal m u s c l e is controlled b y t h e ryanodine receptor, a 550 k D a protein t h a t b i n d s the p l a n t alkaloid r y a n o d i n e at n a n o m o l a r concentrations

(3).

Since the r y a n o d i n e binding site is formed w h e n the c h a n n e l is in the open conformational state, [3H]ryanodine binding activity h a s b e e n widely u s e d as 1 S u p p o r t e d b y International A n e s t h e s i a R e s e a r c h Society, NIH (GM 36852), American H e a r t Association, a n d M u s c u l a r D y s t r o p h y Association. Abbreviations: SIR, sarcoplasmic reticulum; EGTA, ethyleneglycol-bis-(Jlaminoethyl ether)N,N,N',N-tetraacetic acid; Pipes, piperazine-N,N'-bis-(2e t h a n e s u l f o n i c acid). 0006-291X/92 $4.00 595

Copyright © 1992 by Academic Press, Inc. All rights of reproduction in any form reserved.

V o l . 186, No. 1, 1992

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

a powerful index of c h a n n e l activity (4,5). The p u r p o s e of the p r e s e n t s t u d y was to u s e [SHlryanodine binding to investigate the effect of the volatile a n e s t h e t i c s on the conformational s t a t e s of the SR Ca 2+ release c h a n n e l of cardiac a n d skeletal SR.

EXPERIMENTAL PROCEDURES I s o l a t i o n o f r y a n o d t n e receptors. With institutional approval, a d u l t swine were a n e s t h e t i z e d with s u b l e t h a l doses of t h i o b a r b i t u r a t e a n d e u t h a n i z e d by e x s a n g u i n a t i o n . Skeletal m u s c l e was harvested from the v a s t u s a n d trapezius m u s c l e s a n d i m m e d i a t e l y frozen in liquid nitrogen. The entire h e a r t was excised, rapidly dissected free of connective tissue a n d frozen in liquid nitrogen. Skeletal a n d cardiac muscle was t h e n stored at -80°C for later use. Heavy SR was p r e p a r e d from skeletal m u s c l e a n d ventricular free wall by a differential a n d s u c r o s e g r a d i e n t m e t h o d (6) in the presence of protease inhibitors. [nil] ryanodtne binding. All a s s a y s were performed in 800 111 Teflon-capped vials (Kimax, Owens-Illinois) for 120 m i n u t e s at 37°C u s i n g 50-75 lag of SR protein in the presence of 7 nM [3Hlryanodine (60 m C i / m m o l e - D u P o n t New E n g l a n d Nuclear, Boston, MA). Incubation m e d i u m consisted of 750 lal of buffer (Na Pipes 10raM; KCI 0.2 M, pH 7.2), equilibrated with N2 or a N2a n e s t h e t i c m i x t u r e delivered to a reservoir by a calibrated vaporizer t h r o u g h scinterred glass. Isoflurane a n d enflurane were obtained commercially (Anaquest, Madison, WI) a n d thymol-free h a l o t h a n e was generously provided by Halocarbon Laboratories (Augusta, NC). Free Ca 2÷ was 10 .5 M in all experiments, except in t h a t a d d r e s s i n g the calcium d e p e n d e n c e of ryanodine binding. The stability c o n s t a n t s of Fabiato (7) were u s e d to prepare CaC12EGTA (1 raM) buffers to set free [Ca 2÷] at the desired value. All a s s a y s were completed in quadruplicate. At the end of the i n c u b a t i o n period, 24 samples were filtered s i m u l t a n o u s l y t h r o u g h W h a t m a n G F / C filters u s i n g a Brandel Cell Harvester (Brandel, Gaithersberg, MD) a n d c o u n t e d by liquid scintillation. The specific binding was calculated as the difference between the b i n d i n g in the abscence (total binding) and the presence of (nonspecific binding) 100 pM unlabeHed ryanodine.

M e a s u r e m e n t o f a n e s t h e t i c c o n c e n t r a t i o n s . At the end of the i n c u b a t i o n period, b u t before filtering, 25 pl was aspirated from the h e a d space gas (approximately 50 lai) in each vial with a gas-tight syringe. The concentration was m e a s u r e d b y gas c h r o m a t o g r a p h y (Varian Model 3100, Sugarland, TX) with a flame ionization detector a n d referenced to calibration gases commercially p r e p a r e d in N2 (Scott Medical Products, Plumsteadville, PAL The m e a n a n e s t h e t i c c o n c e n t r a t i o n for q u a d r u p l i c a t e s a m p l e s was u s e d for t h a t set. The coefficient of variation for gas c h r o m a t o g r a p h i c m e a s u r e m e n t s of s t a n d a r d gases w a s 10% over the course of this s t u d y .

RESULTS Anesthetics were delivered as a gas u s i n g a calibrated vaporizer into the

[aH]ryanodine binding reaction mixture. The 596

protocol

(see Methods)

Vol. 186, No. 1, 1992

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

~0

300 •

~

r..)







mm

200

!i ,,° 100

i

i

1

2

[HALOTHANE], vol%

FiRure I. Dose-response effect of halothane on cardiac (squares) and skeletal (circles) [3H]ryanodine binding, plotted as percent of control binding (no halothane). The solid line represents a linear regression of the data shown (r=0.92). Each data point the mean of four separate assays.

ensured

that

anesthetics

would

be

equilibrated with

the

SR-cont ai ni ng

a q u e o u s p h a s e in t he s a m e w a y as would o c c u r w h e n t i s s u e is exposed to a n a n e s t h e t i c /n s/tu. Fig. 1 (filled s q u a r e s ) s h o w s t h a t h a l o t h a n e c a u s e d a dose-dependent

stimulation

of

[3Hlryanodine

binding

to

cardi ac

SR.

S t i m u l a t i o n w a s linear over t he clinical c o n c e n t r a t i o n r a n g e of 0.5 to 2 v o l u m e p e r c e n t , w h i c h c o r r e s p o n d s to a n a q u e o u s p h a s e c o n c e n t r a t i o n of 0.25 to 1 mM h a l o t h a n e at r o o m t e m p e r a t u r e . Actual c o n c e n t r a t i o n s at the end

of t h e i n c u b a t i o n period were verified b y gas c h r o m a t o g r a p h y . The

stimulatory

effect of h a l o t h a n e

receptor inasmuch

was

specific for t h e

as h a l o t h a n e h a d

cardi ac

ryanodine

little or no effect on [3H]ryanodine

b i n d i n g to r y a n o d i n e r e c e p t o r s of skeletal m u s c l e

a s s a y e d in a similar

m a n n e r (open circles). In s e p a r a t e e x p e r i m e n t s (not shown), h a l o t h a n e also h a d n o effect on [3H]ryanodine b i n d i n g to b r a i n r y a n o d i n e r e c e p t o r s a s s a y e d in r a b b i t b r a i n m i c r o s o m e s (8). T h u s t he effect was specific for t he cardiac i s o f o r m in spite of t he fact t h a t car diac a n d b r a i n r y a n o d i n e r e c e p t o r s are s t r u c t u r a l l y h o m o l o g o u s (9). Fig.

2

compares

the

effect of h a l o t h a n e

with

that

of two

other

c o m m o n l y u s e d a n e s t h e t i c s , t he s t e r e o i s o m e r s isoflurane a n d enflurane. T he three

anesthetics

separately on

were

cardiac

tested

at

a

c o n c e n t r a t i o n of 2

volume

(left) or skeletal r y a n o d i n e r e c e p t o r s

percent

(right). B o t h

h a l o t h a n e a n d e n f l u r a n e c a u s e d a significant s t i m u l a t i o n of [3Hlryanodine b i n d i n g to th e car di a c r e c e p t o r while isoflurane h a d no effect. On t he o t h e r h a n d , isoflurane, b u t n o t h a l o t h a n e or enflurane, s t i m u l a t e d [3H]ryanodine b i n d i n g to t h e skeletal r y a n o d i n e receptor. T h u s t h e r e w a s a r e m a r k a b l e 597

Vol. 186, No. 1, 1992

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

~

~o o ~

ISOFLURANE ENFLURANE

Ill

300

.OTHANE

250

.ge ~

150

ii o° ta

50 CARDIAC

SKELETAL

Figure 2. Effect of isoflurane, enflurane and halothane (2 vol%) on [3Hlryanodine binding to cardiac (left) and skeletal (right) SR vesicles, plotted as a percent of control binding (no anesthetic). Each bar represents the mean of two experiments, each completed in quadruplicate assays. Error bars represent the standard deviations of duplicate experiments for each anesthetic.

selectivity of receptors.

each

Since

anesthetic

[3Hlryanodine

for

either

binding

cardiac

varies

or

with

skeletal free

ryanodine

Ca 2÷ (10),

we

investigated t h e Ca2*-dependence of t h e s t i m u l a t i o n p r o d u c e d b y h a l o t h a n e in c a r d i a c SR. Fig. 3 shows the Ca2*-dependence of [3H]ryanodine b i n d i n g in t h e a b s c e n c e (triangles) or p r e s e n c e (circles) of 2 v o l u m e p e r c e n t a n e s t h e t i c . In

controls,

the

Ca2+-dependence w a s

bell-shaped

with

a

maximum

at

a p p r o x i m a t e l y 10 pM. H a l o t h a n e s t i m u l a t e d binding over t h e entire r a n g e of free Ca 2÷ w i t h o u t p r o d u c i n g a change in the overall s h a p e of the curve.



CONTROL



HALOTHANE 2%

125

/

/

o"'-,

///

~S

50



, "'',

/

25

"~

"

"'O

m~ -9

-8

-7

-6

-5

-4

-3

-2

log [Ca], M Figure 3. Calcium dependence of [3H]ryanodine binding in the abscence (triangles) and presence (circles) of 2% halothane. Each data point represents a single experiment performed with quadruplicate assays. 598

Vol. 186, No. 1, 1992

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

DISCUSSION

C o n t r a c t i o n s t u d i e s in isolated myocardial t i s s u e myofibrfls

(14),

halothane,

the

and

isolated

most

widely

myocytes studied

(15-17), anesthetic,

(Ii-13),

have

skinned

suggested

decreases

the

that net

s e q u e s t r a t i o n of Ca 2÷ by the SIL Exposure of cardiac t i s s u e to h a l o t h a n e leads to myocardial depression a n d negative inotropy (11-13). Our results are c o n s i s t e n t with a direct effect of h a l o t h a n e on t h e cardiac Ca 2÷ release c h a n n e l since a d o s e - d e p e n d e n t stimulation of [3H]ryanodine binding was evident in the clinical range of anesthetic delivered to SR in a g a s e o u s form. The s t i m u l a t i o n of binding suggested t h a t h a l o t h a n e increases

C a 2÷

release

c h a n n e l activity. This conclusion is based on the generalized finding t h a t ligands t h a t e n h a n c e

C a 2÷

release from the SR also e n h a n c e [3H] ryanodine

binding, w h e r e a s ligands t h a t inhibit Ca 2+ release also inhibit [3H]ryanodine b i n d i n g (10). Hence, the open conformational state of the receptor a p p e a r s to r e p r e s e n t the high affinity binding site for ryanodine a n d binding site d e n s i t y therefore serves as a n indicator of the fraction of receptors t h a t are present, a t a given ligand concentration, in an open conformation. At this point however, we do n o t k n o w w h e t h e r h a l o t h a n e only increases [3H]ryanodine b i n d i n g site density, as would be required by the interpretation above, or if m a y also increase [3H]ryanodine binding site aff'mity. In the latter case, a n e s t h e t i c effects on

[3H]ryanodine binding activity m a y not be directly

related to c h a n g e s in c h a n n e l gating. Nevertheless, the increase of cardiac [3H]ryanodine b i n d i n g produced by h a l o t h a n e a n d enflurane, b u t n o t by isoflurane, is c o n s i s t e n t with a n alteration of gating b e c a u s e isoflurane c a u s e s m u c h less myocardial depression t h a n the other a n e s t h e t i c s (11-13). The idea t h a t anesthetics m a y affect Ca 2÷ release c h a n n e l gating is also s u p p o r t e d by the Ca2*-dependence of h a l o t h a n e stimulation. The Ca z÷ d e p e n d e n c e of [3H]ryanodine binding h a s been interpreted to reflect the b i n d i n g of Ca 2÷ to a high affinity a n d a low affinity site controlling c h a n n e l gating (10). T h u s , Ca 2÷ binding to a high affinity site would increase the open probability of the channel, leading to a n increase in the d e n s i t y of sites available for [3H]ryanodine binding. Conversely, Ca z÷ b i n d i n g to a low-affinity site would close or inactivate the c h a n n e l a n d t h u s decrease the n u m b e r of binding sites. Within this scheme, the major effect of h a l o t h a n e a p p e a r e d to be a n increase in the Ca 2÷ sensitivity to b o t h the high a n d low-affinity Ca 2÷ binding sites controlling c h a n n e l gating. The

selective interaction

of enflurane with

cardiac

receptors

and

isoflurane with skeletal receptors is significant since t h e s e two a n e s t h e t i c s 599

Vol. 186, No. 1, 1992

are

methyl-ethyl

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

ether

isomers.

These

results

suggest

site-specifc

interactions of the a n e s t h e t i c s with each receptor type. Skeletal a n d cardiac r y a n o d i n e receptor isoforms are different

pharmacologic

responses

only =60% homologous (17), to

various

ligands

was

not

so t h a t totally

unexpected. Yet volatile a n e s t h e t i c s are simple h y d r o c a r b o n s w h i c h have been proposed to act on ion c h a n n e l s t h r o u g h a n o n - p r o t e i n m e d i a t e d interaction. Specifically, volatile a n e s t h e t i c s are classically t h o u g h t to alter b u l k m e m b r a n e lipid properties in the vicinity of protein c h a n n e l s (18). This explanation s e e m s less plausible, at least for the Ca 2÷ release c h a n n e l of SR, since enflurane a n d isoflurane are chemical isomers with similar physical properties.

The

results

presented

here

may

have

implications

for the

m e c h a n i s m of action of a n e s t h e t i c s in other t i s s u e s as well.

REFERENCES

1. 2. 3. 4. 5.

Brown BR, C r o u t JR. (1971) Anesthesiology 34:236-245. R u s y BF, Komai, H. (1987) Anesthesiology 67:745-766. P e s s a h IN a n d Zimanyi I. (1991) Mol P h a r m a c o l 39:679-689. Meissner G. (1986) J Biol Chem 261:6300-6306. Mickelson JR, Gallant EM, Litterer LA, J o h n s o n KM, Rempel WE, Louis CL. (1988) J Biol C h e m 263:9310-93158. 6. M e i s s n e r G. (1983) J Biol Chem 259:2365-2374. 7. Fabiato A. (1983) Am J Physiology 245:C1-C14. 8. McPherson PS, Kim Y-K, Valdivia H, K n u d s o n CM, T a k e k u r a H, FranziniA r m s t r o n g C, Coronado R, Campbell tiP. (1991) Neuron 7:17-25. 9. O t s u IC H u n t i n g t o n WF, K h a n n a VK, Zorzato F, Green NM McLerman DH. (1990) J Biol C h e m 265(23):13472-13483, 10. Valdivia HH, Hogan K, Coronado R. (1991) Am J Physiol 261:C237C245. 11. L y n c h C, Frazer MJ. (1989) Anesthesiology 70:511-522. 12. Komai H, R u s y BF. (1990) Anesthesiology 72:694-698. 13. H o u s m a n s PR, Murat. (1988) Anesthesiology 69:451-463. 14. S u JY, Kerrick WGL. (1978) Pflugers Arch 375:111-117. 15. Wheeler DM, Rice RT, Hansford RG, L a k a t t a EG. (1988) Anesthesiology 69:578-583. 16. Wilde DW, Knight PR, S h e t h N, Williams BS. (1991) Anesthesiology 74:1075-1086. 17. K a t s u o k a M, Kobayashi BL Ohnishi ST. (1989) Anesthesiology 70:954-960. 18. F r a n k s WP, Lieb WR. (1991) Science 254:427-436.

600